485
views
0
recommends
+1 Recommend
0 collections
    7
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Testicular shield for para-aortic radiotherapy and estimation of gonad doses

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          For radiotherapy of para-aortic and abdominal regions in male patients, gonads are to be protected to receive less than 2% of the prescribed dose. A testicular shield was fabricated for abdominal radiotherapy with 15 MV X-rays ((Clinac 2300 CD, Varian AG) with low melting point alloy (Cerroband). The dimensions of the testicular shield were 6.5 cm diameter and 3.5 cm depth with 1.5 cm wall thickness. During treatment, this shield was held in position by a rectangular sponge and Styrofoam support. Phantom measurement was carried out with a humanoid phantom and a 0.6 cc ion chamber. The mean energy of the scattered photon was calculated for single scattering at selected distances from the beam edge and with different field dimensions. One patient received radiotherapy with an inverted Y field and gonad doses were estimated using calibrated thermo-luminescent detector (TLD) chips. Measured doses with the ion chamber were 7.1 and 3.5% of the mid-plane doses without a shield at 3 and 7.5 cm off-field respectively. These values decreased to 4.6 and 1.7% with the bottom shield alone, and to 1.7 and 0.8% with both bottom and top shields covering the ion chamber. The measured doses at the gonads during the patient’s treatment were 0.5–0.92% for the AP field (0.74 ± 0.17%, n = 5) and 0.5–1.2% for the PA field (0.88 ± 0.24%, n = 5). The dose received by the testis for the full course of treatment was 32 cGy (0.8%) for a total mid-plane dose of 40 Gy. The first-scatter energy estimated at the gonads is around 1.14 MeV for a primary beam of 15 MV for a long axis dimension of 37 cm of primary field. During the patient’s treatment, the estimated absorbed doses at the gonads were comparable with reported values in similar treatments. The testicular shield reported in this study is of light weight and could be used conveniently in treatments of abdominal fields.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: not found

          Surface dose for megavoltage photon beams outside the treatment field.

          Measurements made on photon beams from four different radiotherapy machines have demonstrated that skin dose several centimeters outside the boundary of a treatment field may be as much as 20% of the central axis maximum dose. This surface dose has been measured for an AECL Theratron 80, Siemens Mevatron VI, Varian Clinac 20, and CGR Sagittaire for distances up to 12 cm outside the field boundary and for depths up to the depth of maximum central axis dose. This dose has also been measured as a function of field size and of source-to-skin distance. For the lower energy photon beams, this radiation is significantly attenuated in the first 2-3 mm of tissue, while for higher energy beams, a buildup phenomenon with a dmax of 2-3 mm is observed. The magnitude of this radiation is approximately linearly dependent upon field dimension for all energies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes?

            To evaluate the influence of different shielding conditions and field geometry on the scatter dose to the remaining testicle during postoperative radiotherapy (RT) in seminoma. Testicular dose measurements were made with LiF thermoluminescent dosimeters (TLD) in 29 patients with stage I and IIA seminoma. The target volume consisted of para-aortic (PA) and para-aortic and homolateral iliac (PAI) lymph nodes in 14 and 15 patients, respectively. All patients had a scrotal shield as well as an additional block extending 7 cm inferiorly from the caudal field edge to shield the testicle from external scatter and collimator leakage. Doses with and without testicular blocks were measured for all patients. In seven patients treated exclusively to the PA region the gonadal dose was assessed according to four different shielding conditions: without any protection, with a gonadal shield alone, with the addition of an inferior field border block to the gonadal shield, and with the field border block alone. For patients treated with PAI fields the mean testicular doses per fraction were 3.89 cGy (S.D. +/- 1.44) and 1.48 cGy (S.D. +/- 0.51) without and with gonadal shielding, respectively (P-value < 0.001); the corresponding values for PA fields were 1.86 cGy (S.D. +/- 0.86) and 0.65 cGy (S.D. +/- 0.35). For the patients treated to the PA region and assessed according to the four different shielding conditions, the additional external block to the testicular shield did not reduce significantly the measured dose on the testis. These results suggest a benefit of gonadal shielding even in seminoma patients undergoing radiotherapy limited to the para-aortic region.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Peripheral dose to the testes: the design and clinical use of a practical and effective gonadal shield.

              A simple and practical gonadal shield has been developed for use near megavoltage radiation fields. The lead shield encloses only the testes, allowing its use with nearly any radiation field that does not include the testes. The dose to the testes with and without the shield has been measured extensively both in phantoms and on patients. The gonadal shield allows a 3 to 10-fold reduction in dose to the testes depending primarily on the distance from the field edge to the gonads. When the shield is used, the gonadal dose is always less than 1% of the patient's prescription dose. Based on our patient studies of testicular injury following conventionally-fractionated irradiation, a dose of less than 50 cGy (1% of a typical 5000 cGy treatment regimen) should preserve normal testicular function.
                Bookmark

                Author and article information

                Journal
                J Med Phys
                JMP
                Journal of Medical Physics / Association of Medical Physicists of India
                Medknow Publications (India )
                0971-6203
                1998-3913
                Oct-Dec 2008
                : 33
                : 4
                : 158-161
                Affiliations
                Medical Physics Unit, National Oncology Center, Royal Hospital, Sultanate of Oman
                [1 ]Department of Radiotherapy, National Oncology Center, Royal Hospital, Sultanate of Oman
                Author notes
                Address for correspondence: Dr. R. Ravichandran Medical Physics Unit, National Oncology Center, Royal Hospital, PB1331, PC111, Seeb, Muscat Sultanate of Oman. E-mail: ravichandranrama@ 123456rediffmail.com
                Article
                JMP-33-158
                10.4103/0971-6203.44477
                2772052
                19893710
                b5a38f0e-5621-4509-be0f-71d918a6219c
                © Journal of Medical Physics

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 18 May 2008
                : 26 October 2008
                Categories
                Original Article

                Medical physics
                clinical dosimetry,para-aortic radiotherapy,gonadal shield,stray radiations
                Medical physics
                clinical dosimetry, para-aortic radiotherapy, gonadal shield, stray radiations

                Comments

                Comment on this article